Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir.
about
Influence of immune activation and inflammatory response on cardiovascular risk associated with the human immunodeficiency virusHIV infection and cardiovascular diseaseUntangling the Gordian knot of HIV, stress, and cognitive impairmentDifferential adipose tissue gene expression profiles in abacavir treated patients that may contribute to the understanding of cardiovascular risk: a microarray studySwitch to Ritonavir-Boosted versus Unboosted Atazanavir plus Raltegravir Dual-Drug Therapy Leads to Similar Efficacy and Safety Outcomes in Clinical PracticeCardiovascular Complications of HIV in Endemic Countries.Atherosclerotic Cardiovascular Disease and Anti-Retroviral Therapy.Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results.Reduced sTWEAK and increased sCD163 levels in HIV-infected patients: modulation by antiretroviral treatment, HIV replication and HCV co-infection.Initiation of antiretroviral therapy at high CD4 cell counts: does it reduce the risk of cardiovascular disease?Inflammation, Immune Activation, and Antiretroviral Therapy in HIVSwitch to raltegravir decreases soluble CD14 in virologically suppressed overweight women: the Women, Integrase and Fat Accumulation Trial.Can early therapy reduce inflammation?Impact of randomized antiretroviral therapy initiation on glucose metabolismChronic HIV disease and activation of the coagulation systemImmune activation and HIV persistence: implications for curative approaches to HIV infection.Comparative impact of antiretroviral drugs on markers of inflammation and immune activation during the first two years of effective therapy for HIV-1 infection: an observational study.Reductions in Plasma Cystatin C After Initiation of Antiretroviral Therapy Are Associated With Reductions in Inflammation: ACTG A5224s.Late Antiretroviral Therapy (ART) Initiation Is Associated with Long-Term Persistence of Systemic Inflammation and Metabolic Abnormalities.Differential Reduction in Monocyte Activation and Vascular Inflammation With Integrase Inhibitor-Based Initial Antiretroviral Therapy Among HIV-Infected Individuals.Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration.Comparison of cardiovascular disease risk markers in HIV-infected patients receiving abacavir and tenofovir: the nucleoside inflammation, coagulation and endothelial function (NICE) study.Factors Associated With Plasma IL-6 Levels During HIV Infection.Vitamin D and Calcium Attenuate Bone Loss With Antiretroviral Therapy Initiation: A Randomized Trial.Markers of renal disease and function are associated with systemic inflammation in HIV infection.Ultrasonographic measures of cardiovascular disease risk in antiretroviral treatment-naive individuals with HIV infection.Prevalence and risk factors of low bone mineral density in Korean HIV-infected patients: impact of abacavir and zidovudineAdipose tissue and immune function: a review of evidence relevant to HIV infection.The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavirHIV replication alters the composition of extrinsic pathway coagulation factors and increases thrombin generationHuman immunodeficiency virus and cancer. A population of HIV-infected patients at Hospital de Santa Maria and predictors of cancer.Immuno-haematologic and virologic responses and predictors of virologic failure in HIV-1 infected adults on first-line antiretroviral therapy in Cameroon.Relationships between inflammation, immune activation, and bone health among HIV-infected adults on stable antiretroviral therapy.Associations of inflammatory markers with AIDS and non-AIDS clinical events after initiation of antiretroviral therapy: AIDS clinical trials group A5224s, a substudy of ACTG A5202NRTI backbone in HIV treatment: will it remain relevant?Predictors of Impaired HDL Function in HIV-1 Infected Compared to Uninfected Individuals.Changes in plasma levels of oxidized lipoproteins and lipoprotein subfractions with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy and associations with common carotid artery intima-media thickness: ACTG 5260s.Soluble biomarkers of immune activation and inflammation in HIV infection: impact of 2 years of effective first-line combination antiretroviral therapy.Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s.
P2860
Q26851535-D90C6656-B29C-45D5-AC1F-9A9540F7CD86Q27008915-315770D0-A176-4F09-BC52-DE71D1571FD2Q28067483-0CF3900C-0C0E-4428-A37E-E06DEC4090A4Q28543075-9E40F40B-F31A-4BAB-A34F-A691D7F117E7Q28553066-056F0AE7-4D99-4FE6-9909-D27D610F3CF6Q30244655-9FAF92D5-AE86-49FA-B669-D15DA20F2874Q30248286-267D6E55-5977-497C-82C2-5F273AD89B51Q31118978-54902977-049B-439E-8857-8E2B62F1A3C5Q31152445-6FF6802D-7137-4B9D-B3C3-CF76E83CB9A6Q33649200-EA679B37-7A62-47F9-B950-3AD7D12B9B3BQ33912595-E87D5AC0-FFAE-448A-A966-BF20A3E7BBC5Q33934080-C9AB8381-EEAA-4052-ABDE-2C778ED42194Q34159822-CD387666-DE36-47F3-B0C6-5B42F8C21359Q34205448-ED343F62-1BE9-4F74-8FCD-A9581AF48BC8Q34342368-DC9B009A-78AA-4CB4-9A86-37D36E8168FEQ34351320-6152403A-440E-4DC9-94E6-73BE128DB8E9Q35109483-0596BB77-7737-4409-8397-FEF48A91D761Q35652795-2D3A4D51-4D7E-499C-ACFC-546F1DB5B4B8Q35860942-C8941DBC-72C6-45CF-9B32-5D3B956EC619Q35965242-122F14DD-4D4D-4960-B574-579418CE908AQ35974422-97DEB03B-97FF-442C-9B9B-823A8753B35AQ35977313-199438D6-5200-4B73-AC27-E689F5A18D2CQ36116238-0DFADC10-4658-46A4-883D-983C8B201EC1Q36139186-2784131D-3B85-4E66-9BA9-2A2FCABF2CABQ36170370-FC96AA2E-185F-4514-903D-0C372624C80DQ36206108-057CB8C8-4212-4350-BB44-F423203369DAQ36875816-629E1D38-B3CB-4E70-A117-14033B1730FDQ36917137-D455BE0F-B19C-4204-B822-8D070B5DBFA5Q37187518-2C82A4D7-83E9-4AC5-877C-6AF3E84086D2Q37279429-59B23937-D16E-4DCD-974C-11EF77F52C8DQ37310421-8C63AB15-BCC3-4476-BE54-99EC3DA3BEF1Q37441664-437044C9-1954-4784-8AF4-F8FB913C913CQ37579676-02AC2DFA-B84C-4FFE-8650-9CBB43C096E0Q37589696-18709CF2-8DF1-4260-A031-93F5F6FA667CQ37619346-F8A4F880-69C9-48CA-8E49-1FB1F9D3FED7Q39533858-B1009D09-2984-4C97-AD6D-4E48BD0D5839Q40277330-CFFDE634-EEB6-4834-84DE-4C2F8FE57A84Q40529577-60B25852-5190-47F1-AE71-B553A42B5421Q41257300-6FBAE088-A49F-4EE7-A50E-5E9ECD6AE8B5Q46016007-CC287FBD-DE69-42FD-B4B3-83EA2786C545
P2860
Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Inflammation markers after ran ...... irenz or atazanavir/ritonavir.
@ast
Inflammation markers after ran ...... irenz or atazanavir/ritonavir.
@en
type
label
Inflammation markers after ran ...... irenz or atazanavir/ritonavir.
@ast
Inflammation markers after ran ...... irenz or atazanavir/ritonavir.
@en
prefLabel
Inflammation markers after ran ...... irenz or atazanavir/ritonavir.
@ast
Inflammation markers after ran ...... irenz or atazanavir/ritonavir.
@en
P2093
P2860
P1433
P1476
Inflammation markers after ran ...... irenz or atazanavir/ritonavir.
@en
P2093
Anthony Bloom
Belinda Ha
Camlin Tierney
Douglas Kitch
Eric S Daar
Grace A McComsey
Kathleen Melbourne
Nasreen C Jahed
Neal Fedarko
Paul E Sax
P2860
P304
P356
10.1097/QAD.0B013E328354F4FB
P407
P577
2012-07-01T00:00:00Z